MSK-ACCESS powered with SOPHiA DDM

Non-invasive NGS panel for detection of somatic variants by analysis of ctDNA from blood plasma.

More detailed product information

A comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK) that covers non-invasive cancer genomic profiling and disease monitoring. This NGS panel is designed to detect SNVs, InDels, CNVs and gene fusions in 146 key cancer-associated genes selected from MSK’s solid tumor genomic-profiling assay, MSK-IMPACT®.

List of included genes on demand.

Library preparation is based on hybridization capture technology.
The kit is validated for Illumina NGS sequencers.

The solution also includes the unique SOPHiA DDM platform for secondary and tertiary analysis of the resulting NGS data, which enables:

Analysis based on the GRCh38/hg38 genome
Dual Variant Pre-classification according to ACMG and the SOPHiA algorithm
Creation of virtual panels
Customizable variant filtering and sorting
Trio Familial Variant Analysis
Direct connection to databases, tools and in silico predictors

For more information, please contact us by e-mail: diagnostika@pentagen.cz